OBJECTIVE： To provide reference for improving medicare drug directory access system for innovative drugs in China. METHODS： With entry point of the current status of innovative drugs entering National Basic Medical Insurance，Work Injung Insurance and Maternity Insurance Drug System（Medicare Directcry）， the support degree of medicare system for policy of innovative drugs in China was studied， descriptive statistics and comparative method were conducted to analyze the numbers and waiting time of the grade 1 drugs in Medicare Directory and compare with other countries to provide corresponding policy recommendations. RESULTS & CONCLUSIONS： The innovative drugs in China suffered from less quantity （only accounted 20.17％ to the new drugs approved for marketing over the same period） and long waiting time （the average waiting time of 935 days for entering the directory）. Inappropriate selection method， static adjustment mechanism of medicare drug directory and the lack of collaboration of policy were the main causes.